CREATES Act Has a Penalty Problem
Executive Summary
Republican House Energy and Commerce Committee members say potentially taking a company's revenue for blocking a generic company from obtaining samples, rather than profit, is excessive.
You may also be interested in...
US FDA Seeks Ability To Include More Inactive Ingredient, Excipient Info In Brand Labeling
Additions could help streamline generic development, Center for Drug Evaluation and Research Director Patrizia Cavazzoni says.
Teva Launches First-Ever CREATES Act Suit
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
Teva, In First-Ever CREATES Act Suit, Seeks Help With Fabry Disease Generic Development
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.